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Abstract
Background: Kallistatin, a serpin widely produced throughout the body, has vasodilatory, anti-angiogenic, anti-
oxidant, and anti-inflammatory effects. Effects of diabetes and its vascular complications on serum kallistatin levels
are unknown.
Methods: Serum kallistatin was quantified by ELISA in a cross-sectional study of 116 Type 1 diabetic patients
(including 50 with and 66 without complications) and 29 non-diabetic controls, and related to clinical status and
measures of oxidative stress and inflammation.
Results: Kallistatin levels (mean(SD)) were increased in diabetic vs. control subjects (12.6(4.2) vs. 10.3(2.8) μg/ml, p =
0.007), and differed between diabetic patients with complications (13.4(4.9) μg/ml), complication-free patients (12.1
(3.7) μg/ml), and controls; ANOVA, p = 0.007. Levels were higher in diabetic patients with complications vs.
controls, p = 0.01, but did not differ between complication-free diabetic patients and controls, p > 0.05. On
univariate analyses, in diabetes, kallistatin correlated with renal dysfunction (cystatin C, r = 0.28, p = 0.004; urinary
albumin/creatinine, r = 0.34, p = 0.001; serum creatinine, r = 0.23, p = 0.01; serum urea, r = 0.33, p = 0.001; GFR, r = -0.25,
p = 0.009), total cholesterol (r = 0.28, p = 0.004); LDL-cholesterol (r = 0.21, p = 0.03); gamma-glutamyltransferase
(GGT) (r = 0.27, p = 0.04), and small artery elasticity, r = -0.23, p = 0.02, but not with HbA1c, other lipids,
oxidative stress or inflammation. In diabetes, geometric mean (95%CI) kallistatin levels adjusted for covariates,
including renal dysfunction, were higher in those with vs. without hypertension (13.6 (12.3-14.9) vs. 11.8 (10.5-
13.0) μg/ml, p = 0.03). Statistically independent determinants of kallistatin levels in diabetes were age, serum
urea, total cholesterol, SAE and GGT, adjusted r
2 = 0.24, p < 0.00001.
Conclusions: Serum kallistatin levels are increased in Type 1 diabetic patients with microvascular complications
and with hypertension, and correlate with renal and vascular dysfunction.
Introduction
In diabetes, angiogenesis is disturbed, contributing to
proliferative retinopathy, nephropathy, neuropathy,
atherosclerosis, and impaired wound healing [1-6].
Hyperglycemia, hypertension, dyslipidemia, smoking,
adiposity, inflammation and oxidative stress may pro-
mote vascular complications [1], and some effects of
these stresses may be mediated by disturbances in the
levels of or balance of pro- and anti-angiogenic factors,
such as (anti-angiogenic) kallistatin.
Kallistatin, a tissue-kallikrein selective 427 amino acid
58-60 kD glycoprotein serpin has independent effects as
a vasodilator and modulator of vascular growth, and anti-
angiogenic, anti-oxidant and anti-inflammatory effects
[7-13]. Found in a wide range of human tissues and
fluids, including kidney, myocardium, blood vessels,
plasma, and urine, [14,15], its levels are relevant to dia-
betes, a condition in which angiogenesis is disturbed and
retinal, renal and cardiovascular damage is increased.
Kallistatin may predict and modulate diabetic angiopa-
thy [16,17] and has potential for use as a therapeutic
agent or target [18]. Clinical studies of circulating kallis-
tatin levels are lacking. We hypothesize that, relative to
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people with Type 1 diabetes or its microvascular com-
plications, as a compensatory mechanism, and may be
positively related to levels of retinal, renal and vascular
damage, oxidative stress, inflammation and glycemia.
We undertook a cross-sectional study of serum kallista-
tin levels in well-characterized Type 1 diabetic patients
(with and without vascular complications) and in
healthy controls, and related kallistatin levels to blood
pressure, vascular function, microvascular complications,
and traditional and novel vascular risk factors.
Materials and methods
Subjects and samples
The study, which conforms to the Declaration of Hel-
sinki, was approved by the local Ethics Committee and
each subject gave written informed consent. Patients
were recruited from St Vincent’s Hospital clinics, and
controls were recruited from the community. Exclusion
criteria were: end-stage renal disease (ESRD), cardiac
arrhythmia, inflammatory conditions, recent (<3 months)
stroke, myocardial infarction, surgery (including laser
therapy), infective illness, or diabetic ketoacidosis and
anti-oxidant vitamin supplement intake. History and
examination were performed, and complication status
confirmed by treating clinicians. Retinopathy was
defined as pre-proliferative or proliferative retinopathy
requiring pan-retinal laser treatment. Nephropathy was
defined as albuminuria (>20 μg/minute) in repeated
timed (12 or 24 hour) urine collections in absence of
infection. Even if albuminuria subsequently regressed
to normal range with treatment, subjects were still
categorized as having nephropathy if they met these
criteria. Cardiovascular disease (CVD) was defined as a
documented myocardial infarction or angina with ECG
changes and/or positive cardiac imaging study, a TIA
or stroke, amputation, angioplasty, or vascular bypass
surgery. Fasted subjects were evaluated pre-medication.
Pulse wave analysis, including large and small artery
elasticity (LAE and SAE), which correlate with pulse
wave velocity and brachial artery flow mediated dila-
tion respectively [19], was performed on rested supine
subjects (Pulse Wave™ CR-2000, Hypertension Diagnos-
tics Inc., Eagan, MN, USA), as previously [19-23].
Inter-measurement CVs for LAE and SAE were 7%
and 5% respectively. St. Vincent’sC l i n i c a lC h e m i s t r y
measured HbA1c, full blood exam and ESR, serum
lipids, renal and liver function, and a mid-stream urine
for cell count, albumin/creatinine ratio and culture.
Glomerular Filtration Rate (GFR) was calculated by the
Cockgroft-Gault equation [24]. Research laboratory
blood samples were centrifuged (3000 rpm, 10 min, 4°
C) and aliquots stored (-86°C) until analysis.
Kallistatin levels were quantified by ELISA (R&D Sys-
tems, Inc. Minneapolis, MN). Ninety-six well microplates
were coated with 100 μL/well of mouse anti-human Ser-
pin A4 capture antibody in PBS (2.0 μg/mL), sealed and
incubated overnight at room temperature (RT). Each well
was aspirated and washed (0.05% Tween® 20 in PBS, pH
7.2-7.4) thrice during each washing step. Nonspecific
binding to capture antibody was minimized by addition
of 300 μL 1% filtered BSA in PBS (1 hour, RT). Recombi-
nant human kallistatin standards were diluted to provide
a seven point standard curve up to 8000 pg/mL. Sera
were diluted (1/20000) in 1% BSA in PBS. After washing,
100 μL of each sample and standards were added to wells
(in triplicate), plates sealed and incubated (2 hours, RT).
After washing, 100 μL biotinylated goat anti-human
kallistatin detection antibody in 1% BSA in PBS (200 ng/
mL) were added to each well, sealed and incubated
(2 hours, RT). After washing, 100 μL of streptavidin con-
jugated to horseradish-peroxidase (R&D Systems) were
added per well, sealed and incubated (20 minutes, RT,
not in direct light). After washing, 100 μL1 : 1H 2O2 :t e t -
ramethylbenzidine was added to each well, sealed and
incubated (20 minutes RT, not in direct light). Next, 50
μL2 NH 2SO4 was added to stop the reaction. Absor-
bance (450 nm) (VICTOR3 V™ Multilabel Counter,
PerkinElmer Life And Analytical Sciences, Inc, Waltham,
Massachusetts) was used with best-fit equations for each
standard curve (range 0-8000 pg/mL) to determine the
kallistatin concentration. Intra and inter-assay CVs were
≤2% and <11% respectively.
Inflammation
To complement white cell counts (WCC) and ESR, CRP
was measured by high-sensitivity nephelometry (Dade
Behring, Marburg, Germany) [20-23]. Soluble Cell Adhe-
sion Molecules: vascular cell adhesion molecule-1
(sVCAM-1), intercellular adhesion molecule-1 (sICAM-1)
and endothelial leukocyte adhesion molecule-1
(sE-Selectin) were measured by ELISA (R&D Systems,
Minneapolis, MN, USA) [20-23], with intra-and inter-
assay CVs < 9%.
Serum Cystatin C was assayed by nephelometry
(Dade-Behring, Marburg, Germany). Intra-assay and
inter-assay CVs were 1.8 and 4.7%.
Oxidized (Ox) LDL was measured by ELISA (Mercodia,
Uppsala, Sweden) with CVs < 10% and results expressed
as OxLDL/LDL [23].
Statistics
One-way ANOVA for continuous variables was used
with a Tukey honest significant difference (HSD) post-
hoc test for differences between groups when ANOVA
P-value was <0.05. Comparisons of prevalence of catego-
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tested using Pearson correlation and Spearman rank
coefficients. Non-normally distributed variables (Cystatin
C, serum creatinine, urea, GFR, urinary albumin/creati-
nine ratio, triglycerides, CRP, ESR, WCC and Ox-LDL/
LDL) were log10 transformed and results were expressed
as geometric means (95% confidence intervals). To
determine independent predictors of kallistatin levels
age, gender, diabetes, and other significant correlates
with kallistatin in bivariate analyses were tested in for-
ward stepwise linear regression analysis. Renal function
and inflammation indicators were examined sequentially
and only those giving the strongest model (highest
R-square value) were included in the final analysis. Vari-
ables were included in the final model if p < 0.30, toler-
ance >0.1 and R
2 change in multiple regression >0.03.
Statistical significance was taken at p < 0.05. These sub-
ject numbers have at least 80% power to detect differ-
ences between means of kallistatin in diabetic patients
(including comparisons of those with (DMCx) and
without (DMNoCx) complications) and controls with a
significance level (alpha) of 0.05.
Results
Subject characteristics a r es h o w ni nT a b l e1 .A g e ,g e n -
der, and lipid profiles matched between diabetic and
non-diabetic groups. Fasting glucose and HbA1c levels
were higher in diabetes, but did not differ by diabetes
complication status. Diabetes duration (range 0.1-63
years) and BMI were higher and renal function worse in
those with complications (DMCx) than in non-diabetic
subjects. Only six DMCx subjects had nephropathy
without proliferative retinopathy. Nine diabetic subjects
had macrovascular disease, which in each case was
associated with microvascular complications. Complica-
tion-free diabetic subjects (DMNoCx) had no clinically
evident micro- or macrovascular complications. BMI and
renal function did not differ significantly between control
and DMNoCx subjects. Systolic blood pressure and pulse
pressure were increased and SAE was decreased in DMCx
vs. controls, and these measures were lower in DMNoCx
vs. DMCx, but did not differ from controls. Smoking was
most prevalent in the DMNoCx group. Use of aspirin and
drugs to treat hypertension and dyslipidemia was greatest
in the DMCx group.
Increased kallistatin in diabetes and its complications
Kallistatin levels mean(SD) were increased in the 116
diabetic vs. 29 controls (12.6(4.2) vs. 10.3(2.8) μg/ml;
p = 0.007), and differed significantly between DMCx,
DMNoCx, and controls (ANOVA, p = 0.007) (Figure 1).
Levels were significantly higher in DMCx (13.4(4.9) μg/ml)
than in control subjects, p = 0.01, but did not differ signifi-
cantly between DMNoCx (12.1(3.7) μg/ml) and controls.
Kallistatin levels were higher in DMCx vs. DMNoCx, but
did not reach statistical significance (p = 0.25).
Increased kallistatin concentrations in hypertension in
diabetes and associations with poor vascular health
In diabetic patients, mean(SD) kallistatin levels were higher
i nt h o s ew i t h( n=5 4 )v s .w i t h o u t( n=6 2 )d i a g n o s e d
hypertension (13.5(4.7) vs. 11.8(3.5) μg/ml, p = 0.06).
These groups differed significantly by age, diabetes dura-
tion, BMI, blood pressure, renal function, ESR and CRP,
(not shown), but after adjustment for these covariates,
adjusted mean (95%CI) kallistatin levels remained higher
in those with vs. without hypertension (13.6(12.3-14.9) vs.
11.8(10.5-13.0) μg/ml, p = 0.03). In diabetes, kallistatin cor-
related inversely with SAE, r = -0.23, p = 0.02. In controls
there were no statistically significant correlations with
blood pressure or pulse-wave analysis indices. In the com-
bined group, kallistatin correlated significantly with systolic
and diastolic blood pressure and SAE (all p < 0.05).
Kallistatin level correlate with renal dysfunction
On univariate analyses, in diabetes kallistatin concentra-
tions correlated significantly with cystatin C, r = 0.28;
p = 0.004, calculated GFR, r = -0.25; p = 0.009, urinary
albumin/creatinine ratio, r = 0.34; p = 0.001, serum
creatinine, r = 0.23; p = 0.01 and serum urea, r = 0.33,
p = 0.001. There were no statistically significant (uni-
variate analysis) correlations between kallistatin concen-
trations and renal function in the control group. In the
combined groups kallistatin levels correlated with serum
creatinine, urea, cystatin C, GFR and urinary albumin/
creatinine ratio, (all p < 0.05).
Kallistatin and lipid levels are correlated
In diabetes, kallistatin levels correlated with total choles-
terol, r = 0.28, p = 0.004; LDL-cholesterol, r = 0.21, p =
0.03; and non-HDL-cholesterol, r = 0.21, p = 0.03; but
not with triglycerides or HDL-cholesterol levels. In the
control group, kallistatin levels correlated with total
cholesterol, r = 0.39; p = 0.04, and in the combined
groups with triglycerides, total-, LDL- and non-HDL-
cholesterol (all p < 0.05). Kallistatin levels did not differ
by lipid drug use in any group.
Levels of Kallistatin, a hepatic product, and normal range
liver function correlate
All liver function tests were within the normal range
and levels of aminotransferases and bilirubin did not dif-
fer between diabetic and control groups. In both the
diabetic and the combined diabetes and control groups,
kallistatin levels correlated with gamma-glutamyltrans-
ferase (GGT) (r = 0.27, p = 0.04, and r = 0.25, p = 0.03
respectively), and inversely with bilirubin levels in the
combined groups only, r = -0.22, p = 0.04.
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inflammation or oxidative stress
In both diabetic and control groups, separately and
combined, kallistatin levels did not differ by smoking
status. In the diabetic group, but not in controls, kallis-
tatin levels were significantly higher in females than in
males: (13.3 (4.6) vs. 11.6 (3.4) μg/ml; p = 0.02). On uni-
variate analyses, kallistatin did not correlate with BMI,
measures of oxidative stress, or inflammation (not
shown). In the combined groups kallistatin correlated
with BMI, r = 0.19; p = 0.03, fasting blood glucose, r =
0.22; p = 0.01; and HbA1c, r = 0.26; p = 0.002, but
these correlations were not statistically significant in the
separate diabetes and control groups.
Determinants of kallistatin levels
On forward stepwise linear regression analysis (all sub-
jects), independent determinants of kallistatin were age,
Table 1 Clinical and biochemical characteristics of healthy control subjects and Type 1 diabetic patients with
microvascular complications (DMCx) and without complications (DMNoCx)
Control (CON)
n=2 9
DMNoCx
n=6 6
DMCx
n=5 0
ALL DM
n = 116
P
All DM vs CON
Male gender,% 52 47 40 44
Age, years 41 (14) 38 (14) 41 (14) 39 (14) 0.56
Diabetes duration, years 0 18 (12)
b 27 (13) 22 (13)
BMI, kg/m
2 23.6 (2.9) 24.9 (3.4)
b 27.6 (4.9)
a 26.0 (4.2) 0.004
HbA1c, % 5.1 (0.5) 8.1 (1.3)
a 8.4 (1.2)
a 8.2 (1.3) <0.001
Glucose 4.8 (0.4) 12.9 (5.4)
a 13.2 (5.8)
a 12.9 (5.5) <0.001
Vascular health measures
Systolic BP, mmHg 118 (12) 125 (12)
b 136 (15)
a 130 (15) <0.001
Diastolic BP, mmHg 69 (10) 70 (9)
b 75 (10) 72 (10) 0.16
Pulse pressure, mmHg 49 (8) 55 (8)
a, b 61 (10)
a 57 (9) <0.001
Large artery elasticity, mL/mmHg × 10 18.1 (5.1) 16.7 (5.6) 15.7 (5.0) 16.2 (5.3) 0.082
Small artery elasticity, mL/mmHg × 100 7.7 (2.8) 6.7 (3.0)
b 5.1 (2.7)
a 6.0 (3.0) 0.007
Renal function measures
Serum creatinine, mmol/L 0.08 (0.08-0.09) 0.08 (0.08-0.09)
b 0.10 (0.09-0.11)
a 0.09 (0.09-0.1) 0.06
Serum urea, mmol/L 5.4 (5.0-5.9) 5.2 (4.9-5.6)
b 7.7 (6.6-9.0)
a 6.1 (5.7-6.7) 0.15
Serum Cystatin C, mg/L 0.81 (0.76-0.86) 0.75 (0.72-0.78)
b 0.97 (0.83-1.14) 0.83 (0.78-0.9) 0.76
GFR, ml/s/1.73 m
2 92 (85-100) 99 (93-106)
b 83 (74-95) 92 (87-98) 0.95
Urinary albumin/creatinine ratio mg/mmol 0.50 (0.32-0.77) 0.73 (0.60-0.89)
b 5.41 (2.87-10.18)
a 1.75 (1.24-2.47) 0.003
% on BP drugs 0 18
a, b 70
a 41 <0.001
Lipid profiles and medications
Total cholesterol, mmol/L 5.0 (0.9) 4.8 (1.0)
a 5.4 (0.9) 5.1 (1.0) 0.67
Triglycerides, mmol/L 0.79 (0.64-0.98) 0.88 (0.78-1.00) 1.12 (0.95-1.32)
a 0.98 (0.89-1.08) 0.06
LDL-cholesterol, mmol/L 3.0 (0.8) 2.9 (1.0) 3.1 (0.9) 3.0 (1.0) 0.93
HDL-cholesterol, mmol/L 1.6 (0.4) 1.5 (0.5) 1.6 (0.5) 1.6 (0.5) 0.66
% on lipid drugs 0.4 13 36
a 23 0.01
Inflammation and oxidative stress
White Cell Count, cellsx10
9/L 5.6 (5.2-6.1) 6.2 (5.8-6.7) 7.0 (6.3-7.7)
a 6.5 (6.2-6.9) 0.02
ESR, mm/h 4.8 (3.7-6.3) 7.0 (5.7-8.6)
b 10.9 (8.5-14.3)
a 8.4 (7.1-9.9) 0.002
CRP, mg/L 0.91 (0.58-1.42) 1.46 (1.10-1.95) 1.63 (1.15-2.31) 1.58 (1.27-1.96) 0.03
sICAM-1, ng/mL 250 (42) 296 (53)
a 319 (59)
a 307 (58) <0.001
sVCAM-1, ng/mL 594 (178) 602 (173) 662 (137) 629 (164) 0.36
s-eSelectin, ng/mL 47 (25) 63 (24) 66 (23)
a 64 (23) 0.002
OxLDL/LDL 38 (31-45) 45 (40-51) 44 (38-49) 44 0.12
% current smokers 14 26 9 19 0.36
% on aspirin 3 4 16 9 0.33
Clinical and biochemical characteristics of healthy control subjects and Type 1 diabetic patients with microvascular complications (DMCx) and without
complications (DMNoCx). Continuous data are mean (SD) or geometric mean (95% CI);
a Significantly different from non-diabetic control subjects;
b significantly
different from Type 1 diabetic participants with microvascular complications.
Continuous data are mean (SD) or geometric mean (95% CI);
a Significantly different from non-diabetic control subjects;
b significantly different from Type 1
diabetic participants with microvascular complications.
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GGT (adjusted r
2 = 0.24, p < 0.00001), together
accounting for 24% of variability in serum kallistatin
levels. In diabetes, independent determinants of kallista-
tin were age, SAE, total cholesterol, serum urea and
GGT (adjusted r
2 = 0.24, p < 0.00001). In controls: LAE,
pulse pressure, total cholesterol, glucose, serum urea
and WCC (adjusted r
2 = 0.49, p = 0.002). In each group
and in the combined groups renal function (serum urea)
was the strongest independent determinant (not shown).
Discussion
In a cross-sectional study we identified increased serum
kallistatin levels in Type 1 diabetic patients and in Type
1 diabetic patients with microvascular complications vs.
age and gender-matched non-diabetic subjects. Further,
kallistatin levels were elevated in diabetic subjects with
hypertension vs. those without. There were no statisti-
cally significant differences in kallistatin levels between
complication-free Type 1 diabetic patients and healthy
subjects or between diabetic subjects with or without
vascular complications. In the diabetic subjects consid-
ered as a single group, kallistatin levels were associated
with renal dysfunction, total and LDL-cholesterol levels,
and inversely with SAE, reflecting vascular dysfunction.
Kallistatin levels in diabetes did not correlate with other
lipids, glycemia, BMI, smoking, or measures of inflam-
mation or oxidative stress. Common statistically inde-
pendent determinants of kallistatin levels in all subjects
and in the separate diabetes and control groups were
renal function (most strongly) and cholesterol, with age,
hepatic and vascular function also being related to kal-
listatin level variability in the combined group.
Functions, sources, and levels of kallistatin
Kallistatin has vasodilatory, anti-angiogenic, anti-inflam-
matory and anti-oxidant effects [7-10,12,13]. It is loca-
lized in many human tissues, including eye, kidney,
liver, heart, arteries and veins, atheroma, blood cells and
body fluids [7,14,15,17]. The relative contributions of
various cell and tissue types to circulating kallistatin
levels in health and disease is unknown, but several
studies support liver as a major source [7,14,25]. Hepa-
tocytes secrete kallistatin [7,14,25] and in a small
cross-sectional study of cirrhosis patients, circulating
kallistatin levels were ≈3 0 %t h a to fh e a l t h yp e o p l e[ 1 4 ] .
In our study there were correlations between kallistatin
levels and normal range liver function tests, perhaps in
keeping with a predominant hepatic origin of serum
kallistatin.
Increased kallistatin in diabetes complications
To the best of our knowledge, the only prior study of
kallistatin in human diabetes is by coauthor J-X Ma et al
in which immunoreactive kallistatin levels in vitreous
fluid from 18 patients with diabetic retinopathy were
significantly lower compared to 17 non-diabetic subjects
[17]. We now demonstrate higher serum kallistatin
levels in Type 1 diabetic patients with vascular compli-
cations, which include proliferative retinopathy. We
have noted a similar pattern with another serpin, Pig-
ment Epithelium Derived Factor (PEDF), with low vitr-
eous fluid levels in diabetic retinopathy patients and
high serum levels with microvascular complications
[23]. In the present study, kallistatin levels also related
negatively to renal function, which could be due to
reduced renal excretion or increased production, or
both. Kallistatin has been localized in human urine
[14,26] and in kidneys [7,14,27], where it is thought to
regulate salt and water handling, renal perfusion and
blood pressure, and to reduce intra-renal fibrosis,
inflammation, and oxidative stress [7,12,14,28]. Apart
from the current study, plasma, serum, renal tissue or
urine kallistatin levels have not been reported in human
diabetes or in other renal diseases. It may be that kallis-
tatin levels rise in response to renal disease and protei-
nuria together with other circulating proteins of hepatic
origin [29]. Urinary kallistatin excretion, not measured
in this study as there were no urine kallistatin ELISA
assays, merits future study.
Kallistatin levels are associated with impaired vascular
health
We observed positive associations between kallistatin
and systolic blood pressure and pulse pressure, and an
inverse correlation with SAE. Furthermore, serum kallis-
tatin levels were higher in diabetic patients with vs.
without diagnosed hypertension, even after statistical
Figure 1 Mean (SD) serum kallistatin levels in healthy non-
diabetic control subjects, Type 1 diabetic patients without
complications (DMNoCx) and Type 1 diabetic patients with
complications (DMCx). Kallistatin levels differed between DMCx,
DMNoCx, and controls, ANOVA, p = 0.007; # vs. control subjects p <
0.01.
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ciated with impaired renal function by several measures.
One possibility is that elevated kallistatin levels may be
compensatory to mitigate the high blood pressure and
endothelial dysfunction, as kallistatin is a potent vasodi-
lator [7,10] and lowers blood pressure [30,31]. Other
animal and isolated vascular cell experiments support a
role of kallistatin in vascular biology, including vascular
and cardiac remodeling [7,11] and angiogenesis [8,13].
Kallistatin increases in vitro growth, proliferation and
migration of vascular smooth muscle cells and inhibits
in vitro proliferation, migration, and adhesion of vascu-
lar endothelial cells [13]. In rats, balloon angioplasty
markedly increased kallistatin mRNA and protein
expression in injured vessels, which along with neoin-
tima formation was attenuated by local delivery of kallis-
tatin antisense cDNA [13]. Kallistatin also inhibits
angiogenesis in in vivo rat models of hind-limb ischemia
and tumor growth [8].
Kallistatin and inflammation and oxidative stress
The higher serum levels of inflammation markers
(WCC, ESR and cell adhesion molecules) in diabetes
and/or its complications in the present study are in
keeping with other publications [20,32-34]. In our study,
except for a positive correlation with WCC in controls
on adjusted analyses, kallistatin levels were not signifi-
cantly related to inflammation or oxidative stress mea-
sures. This contrasts with other literature [9,12,35,36].
In people with (inflammatory) rheumatoid arthritis,
plasma and joint kallistatin levels were increased relative
to osteoarthritis patients [35]. In animal studies, kallista-
tin gene delivery has anti-inflammatory and anti-oxidant
effects, inhibiting renal inflammation including renal
CAM expression in a rat renal disease model [12], inhi-
biting inflammation and apoptosis in acute myocardial
ischemia-reperfusion injury [9], and reducing inflamma-
tion and joint injury in rat arthritis models [36]. Kallista-
tin levels decline during sepsis and severe inflammation,
as markedly lower circulating kallistatin levels have been
reported in humans with sepsis [14] and in necrotic
acute pancreatitis [37]. In animal models hepatic kallis-
tatin expression is reduced by lipopolysaccharide (LPS)
[38], and transgenic mice overexpressing human kallista-
tin have lower LPS-induced mortality [39]. These pre-
vious studies support that kallistatin is an anti-
inflammatory factor, but our present cross-sectional
clinical study, in which serum kallistatin levels are not
strongly associated with serum inflammation markers do
not support a major anti-inflammatory role. This may
relate to the level of inflammation in diabetes being
relatively low, local tissue anti-inflammatory effects not
being well-reflected by circulating measures, or to oppos-
ing effects of the effects of inflammation (decreasing
kallistatin) and of renal and vascular dysfunction
(increasing kallistatin).
Angiogenesis and arteriogenesis in atherosclerosis
Neovascularisation, including angiogenesis and arterio-
genesis (the rapid proliferation of pre-existing arterial
vessels, which have a mature tunica media), is required to
heal wounds and for collateral circulation development in
ischemic tissues [40], common problems in diabetic
patients [1,40]. However, angiogenesis within atheroma-
tous plaques may be deleterious as leaky new vessel for-
mation may promote inflammation, plaque growth,
hemorrhage, instability, and rupture [40-43]. There is
likely a delicate balance between pro- and anti-angio-
genic factors, which likely varies at the different stages of
blood vessel formation and repair and plaque formation,
stability and regression. It is currently controversial as to
whether pro- or anti-angiogenic factor based therapies
will benefit atherosclerosis [44-46]. PEDF, another mem-
ber of the serpin family, is now undergoing evaluation as
a potential therapeutic agent for ocular angiogenesis [47].
The specific role and potential therapeutic effects of kal-
listatin in vascular disease, including atheroma progres-
sion and plaque stability, and specifically in the context
of diabetes, remains unclear.
Study limitations and future research
The limitations of a cross-sectional study are recognized,
and kallistatin responses may vary by tissue in ways not
necessarily reflected in serum levels. Longitudinal stu-
dies of kallistatin and the various types of diabetic com-
plications are desirable. As higher kallistatin levels were
inversely related to renal function, even in our study
groups with relatively normal renal function, such as
reflected by serum creatinine and urea, kallistatin levels
in urine and in serum of people with different types and
degrees of renal damage are merited. As we observed
associations between kallistatin and blood pressure,
vascular dysfunction, lipids and renal function, studies
pre- and post-interventions targeting these factors are
merited. Wound healing studies, mechanistic vascular
reactivity studies involving diabetic animals, isolated ves-
sels and plaque and cell culture models are relevant.
Future studies may utilize additional measures of
inflammation and oxidative stress.
Conclusions
Increased serum kallistatin levels are associated with
diabetic microvascular complications, hypertension and
vascular dysfunction, renal dysfunction and elevated
cholesterol, but not with measures of inflammation or
oxidative stress. Whilst kallistatin’s vasodilatory, poten-
tial anti-inflammatory and anti-oxidant effects may be
beneficial; its potent anti-angiogenic effects may delay
Jenkins et al. Journal of Angiogenesis Research 2010, 2:19
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Page 6 of 8wound healing, impair collateral vessel formation and
accelerate atherosclerosis.
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